BiotechTube

Interferon Beta-1A

Phase 1/2Withdrawn
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Recurrent B Acute Lymphoblastic Leukemia

Conditions

Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma

Trial Timeline

Apr 1, 2025 → Oct 30, 2027

NCT ID
NCT05936229

About Interferon Beta-1A

Interferon Beta-1A is a phase 1/2 stage product being developed by Faron Pharmaceuticals for Recurrent B Acute Lymphoblastic Leukemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05936229. Target conditions include Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05936229Phase 1/2Withdrawn

Competing Products

20 competing products in Recurrent B Acute Lymphoblastic Leukemia

See all competitors
ProductCompanyStageHype Score
KPL-914Kiniksa PharmaceuticalsPhase 2
47
KPL-387Kiniksa PharmaceuticalsPhase 2
47
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
72
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
Zopapogene imadenovec (Zopa)PrecigenApproved
80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
36
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
52
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
33
PLX3397Daiichi SankyoPhase 2
52
erlotinib + etoposideAstellas PharmaPhase 2
52
Drug Combination TherapySun PharmaceuticalPhase 2
52
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
Eribulin MesylateEisaiPre-clinical
23
Lenvatinib + EverolimusEisaiPhase 1/2
41
E7090EisaiPhase 2
52
LenvatinibEisaiPhase 2
52

Other Products from Faron Pharmaceuticals

Interferon beta-1a + PlaceboPhase 3
69
Interferon Beta-1A + PlaceboPhase 2
44
IFN beta-1a + DexamethasonePhase 2
44
bexmarilimabPhase 1/2
33
FP-1305 (bexmarilimab)Phase 1/2
33